| Symbol | INVA |
|---|---|
| Name | INNOVIVA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1350 OLD BAYSHORE HIGHWAY,SUITE 400, BURLINGAME, California, 94010, United States |
| Telephone | +1 650 238-9600 |
| Fax | — |
| — | |
| Website | https://www.inva.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001080014 |
| Description | Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravances respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Additional info from NASDAQ: |
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Read moreBasso Stephen 🟡 adjusted position in 564 shares of Innoviva, Inc. (INVA) at $22.24 Transaction Date: May 20, 2026 | Filing ID: 236913
Read moreRaifeld Pavel 🟡 adjusted position in 7 shares of Innoviva, Inc. (INVA) at $22.24 Transaction Date: May 20, 2026 | Filing ID: 236910
Read moreZhen Marianne 🔴 sold 1.1K shares of Innoviva, Inc. (INVA) at $22.24 Transaction Date: May 20, 2026 | Filing ID: 236907
Read moreLinden Josephine 🟢 acquired 24.4K shares (1 derivative) of Innoviva, Inc. (INVA) at $21.80 Transaction Date: May 18, 2026 | Filing ID: 232638
Read moreNew Form 3 - Innoviva, Inc. <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001193125-26-232616 <b>Size:</b> 3 KB
Read more